Group 1 - The 17th China Bioindustry Conference highlighted the theme "Biotechnology Empowering the Future, Biomanufacturing Reshaping the World," showcasing the latest achievements in China's biotechnology and biomanufacturing sectors [1] - Wuhan has developed a comprehensive biopharmaceutical industry cluster, with a scale exceeding 550 billion yuan, playing a significant role in both national and global biomanufacturing [1] - The "China Bioeconomy Development Report 2025" indicates that China ranks second globally in research centers and is a major player in the biopharmaceutical market, gradually participating in international competition [1][2] Group 2 - In 2024, China approved 93 new drugs, the highest in five years, and is now the second-largest biopharmaceutical market globally, with a growing number of research drugs [2] - China leads the world in medical device patent applications, with 91,513 applications, accounting for nearly 70% of the global total [2] - The Hubei Pathology Big Data Database is expected to exceed 5 million high-precision digital slices by the end of 2025, significantly enhancing medical institutions and driving innovation [2] Group 3 - China's bioeconomy is robust, with a steady growth trend, and the global bioeconomy is projected to grow from $40-50 trillion to $30 trillion by 2050, with a compound annual growth rate of 8.6% [3] - Advances in synthetic biology and high-throughput screening technologies have led to significant breakthroughs in the production of pharmaceutical chemicals using microbial cell factories [3] - In the field of agricultural biotechnology, China accounts for 23% of the global market share in biological breeding, which has effectively reduced production costs and pesticide usage [3]

Core Viewpoint - The article emphasizes the importance of industrial biotechnology in supporting China's sustainable development and innovation in the bio-economy, focusing on key technologies and research areas that can replace fossil resources with renewable carbon resources and enhance industrial processes through modern biotechnology [5][20]. Group 1: Research Focus - The research institute focuses on three strategic themes: replacing fossil resources with renewable carbon resources, using clean biological processing instead of traditional chemical methods, and enhancing industrial levels through modern biotechnology [5]. - Key research areas include industrial protein science and biocatalysis engineering, synthetic biology and microbial manufacturing engineering, and biological systems and bioprocess engineering [5]. Group 2: Team Introduction - Zhang Yiheng, a prominent researcher and doctoral supervisor, leads the Low Carbon Synthesis Engineering Biology National Key Laboratory and has made significant contributions to the field, including the establishment of the in vitro BioTransformation (ivBT) engineering technology system [6]. - Zhang Yuzhen, another researcher, has developed microfluidic technologies for quantitative studies of microbial populations and is working on high-throughput identification techniques for important industrial enzymes [7][8]. Group 3: Recruitment Information - The institute is seeking to hire 2-3 postdoctoral research assistants and 1-2 assistant researchers, with a focus on candidates holding doctoral degrees in microbiology, molecular biology, or enzyme engineering [9][10]. - Competitive salaries and benefits are offered, including social insurance, housing funds, and opportunities for professional development and overseas visits [11][12]. Group 4: Career Development - Postdoctoral researchers can apply for permanent positions with competitive salaries and development opportunities, including potential advancement to senior technical roles based on their research achievements [13][14]. Group 5: Upcoming Events - The article mentions an upcoming forum on non-grain biomass high-value utilization, scheduled for January 27-29, 2025, in Hangzhou, focusing on clean pretreatment of biomass and commercialization of bio-based materials and fuels [20].

Group 1 - The core innovation is the AI-designed MyD88 inhibitor, which is a groundbreaking anti-inflammatory drug aimed at treating autoimmune diseases and tumors [1][2] - The MyD88 protein is a critical immune checkpoint and a target for various inflammatory diseases, but traditional drug development has struggled due to the lack of suitable binding structures [1][2] - The AI-assisted design has led to seven candidate drugs entering clinical development, with one already in Phase II trials showing promising efficacy [2] Group 2 - China is promoting industrial innovation through the "AI + Pharmaceuticals" initiative, aiming to develop a new paradigm for drug research and development [3] - The 17th China Bio-Industry Conference highlighted the potential of biomanufacturing as a key driver of the Fourth Industrial Revolution, with significant market opportunities [3] - The report indicates that by 2024, China will rank second globally in the number of drugs under research, narrowing the gap with the United States [5]

Core Insights - The 17th China Bio-Industry Conference opened on September 4, focusing on "Biotechnology Empowering the Future, Biomanufacturing Reshaping the World" with an emphasis on "high-end, professional, international, and market-oriented" approaches [1] Group 1: Event Overview - The conference showcased numerous well-known companies presenting cutting-edge technologies, products, and applications, highlighting the latest advancements in the global bio-industry [1] Group 2: Exhibitor Highlights - BGI Genomics displayed tissue slices applied in spatiotemporal chips [3] - The Optics Brain-Computer Interface and near-infrared brain function imaging device from the Optics Valley Biocity exhibition area attracted significant attention from foreign guests [4] - United Imaging Healthcare presented a 5T magnetic resonance imaging system [6] - Heyuan Bio showcased recombinant human albumin injection (from rice) [7]

Core Insights - China has become the second largest biopharmaceutical market globally, meeting domestic demand while gradually participating in international market competition [1] - The report highlights China's leading position in areas such as research and development of biopharmaceuticals, brain-computer interfaces, and high-precision digital slicing [1] Industry Developments - In 2024, the National Medical Products Administration of China approved 93 new drugs, marking a five-year high, with China ranking second globally in the number of drugs under research [2] - Four Chinese companies made it to the top 25 global pharmaceutical companies in terms of R&D pipeline scale, setting a new historical record [2] - China published over 20,000 SCI papers in the medical equipment field in 2024, leading the world in research output [2] - The biopharmaceutical industry in China accounts for over 30% of global innovative drugs, research pipelines, and newly listed drugs [2] Economic Impact - The value of bio-based materials and chemicals has surpassed 1 trillion yuan, with the contribution of the bio-economy to GDP exceeding 7% [2] - China has established 23 biopharmaceutical industry bases, leading globally in the number of biotechnology patent applications and R&D personnel [2] International Collaboration - The conference attracted Cuba's largest state-owned pharmaceutical group, highlighting successful collaboration in biotechnology between China and Cuba [3] - Jointly developed drugs, such as the EGFR monoclonal antibody for cancer treatment, have benefited over 50,000 Chinese patients [3]

Group 1 - The 17th China Bio-Industry Conference highlighted that China has become the second-largest biopharmaceutical market globally, meeting domestic demand while gradually participating in international market competition [1] - The report indicates that China is in a leading position in areas such as biopharmaceuticals under research, brain-machine interfaces, and high-precision digital slicing [1] - The global focus on biomanufacturing and circular economy strategies is increasing, with significant funding for gene and cell engineering research, biomass utilization, and the development of bioproducts [1] Group 2 - In 2024, China approved 93 new drugs, the highest in five years, and ranks second globally in the number of drugs under research [2] - Four Chinese companies made it to the top 25 global pharmaceutical companies in terms of R&D pipeline scale, marking a historic achievement [2] - China leads the world in the number of SCI papers published in medical equipment, with over 20,000 papers in 2024, showcasing strong research resources and innovation capabilities [2] Group 3 - The National Development and Reform Commission reported that China has established 23 biomanufacturing bases, leading in biotechnology patent applications and R&D personnel [2] - The biopharmaceutical industry in China ranks second globally, with innovative drugs, research pipelines, and newly approved drugs accounting for over 30% of the global total [2] - The value of biobased materials and chemicals has surpassed 1 trillion yuan, with the contribution of the bio-economy to GDP exceeding 7% [2] Group 4 - The conference featured over 200 renowned institutions and companies, showcasing more than 1,000 products, including several global firsts [2] - Notable innovations included a multimodal sensing system for brain rehabilitation and a world-first 5.0T whole-body MRI system [3] - The collaboration between China and Cuba in biotechnology was highlighted as a successful partnership, with joint research and production benefiting both nations [3]

Group 1: Overview of China's Biomanufacturing Industry - The value added by the biomanufacturing sector accounts for over 7% of China's GDP [4] - China ranks second globally in the number of CAR-T cell therapy research centers and the number of biopharmaceuticals under research [1][4] - The biopharmaceutical market in China has surpassed 1.1 trillion yuan, with a significant number of innovative drugs and research pipelines [5] Group 2: Innovations and Developments - The "National Innovation Drug Insight System" was launched to enhance the efficiency of innovative drug development and address industry challenges [7] - The Hubei Pathology Big Database has reached 170,000 high-precision digital slices, positioning it as the second largest globally [6] - The global CAR-T clinical research centers have increased by 60% from 2020 to 2024, with China contributing 388 centers [5] Group 3: Market Growth and Future Projections - The global biomanufacturing market is projected to grow significantly, with the biobased chemicals market expected to reach $125.23 billion by 2029 [8] - China's biomanufacturing sector is positioned as a new engine for economic growth, supported by national policies and strategic planning [8] - The biotechnological innovations in agriculture, such as genetically modified crops, are set to enter the industrialization demonstration phase in 2024 [9]

"展"的板块。本届展会采取"线上+线下"双线融合展示模式，线下展厅设在中国光谷科技会展中心。 10000平方米大型专业展览，规划综合形象展区、生物制造体验展和未来发展展区三大板块，系统展示 国内外生物产业基地、科研机构及头部企业的最新成果、创新实践。 本次展会致力于打造国际级的"生物产业风向标"，让公众一站式领略中国生物产业的发展水平和创新活 力。展会现场，武汉禾元生物、高科医疗器械园、嫦娥生物等多家龙头企业纷纷亮相，200余家企业和 机构展出千余件展品。 "赛"的板块。本届大会同步举行"2025生物制造创新创业大赛"总决赛，举行中国生物产业大会2025生物 制造创新创业大赛颁奖及创新力榜单发布仪式。 （原标题：第十七届中国生物产业大会在汉开幕） 经济观察网 程久龙 实习生 刘轩宇 9月4日上午，第十七届中国生物产业大会在武汉·中国光谷科技会展 中心隆重开幕。本届大会紧扣国家"十四五"生物经济发展规划、"十五五"前瞻布局，以"生物科技赋能 未来·生物制造重塑世界"为主题展开，集中展示了我国生物科技与生物制造领域的最新成果、发展趋 势，凸显了中国生物经济的高质量发展和新质生产力的提升，同时也为国际间开展生物产业 ...

Group 1 - The event commemorating the 80th anniversary of the victory in the Chinese People's Anti-Japanese War and the World Anti-Fascist War was held at Tiananmen Square, Beijing, with significant participation from Jiangsu province [1][2] - Jiangsu residents expressed deep emotions and pride during the live broadcast of the military parade, showcasing advanced military equipment and honoring historical sacrifices [2][3] - The event served as a reminder of the importance of remembering history and the sacrifices made by past generations, with various individuals reflecting on their roles in preserving peace and national strength [3][4] Group 2 - The spirit of the Anti-Japanese War is seen as a source of strength for the people of Jiangsu, with institutions like the Liu Laozhuang Martyrs Memorial Hall committed to passing down heroic stories [3][4] - The military and civilian sectors are encouraged to uphold the legacy of the Anti-Japanese War by continuing to strive for excellence and innovation in their respective fields [4][5] - The commitment to national security and social order is emphasized by law enforcement agencies, highlighting the ongoing responsibility to protect peace and stability [4][5]

Group 1 - The "Zhihui Shanxi" expert talent summer camp focused on the transformation and reform demonstration area in Shanxi, gathering over 200 experts and scholars from various universities to discuss innovation and high-quality development in the biopharmaceutical industry [1][2] - Shanxi's transformation demonstration area has established high-level scientific innovation platforms and produced several innovative results, including humanized collagen and innovative anti-cancer drugs, marking a significant step towards high-quality development in the biopharmaceutical industry [1][2] - The event included keynote speeches, industry sharing, roundtable discussions, and enterprise services aimed at promoting deep integration of industry, academia, and research, exploring cutting-edge technologies in synthetic biology and biopharmaceuticals [1][2] Group 2 - Professor Zeng Anping from the German Academy of Engineering delivered a keynote report on synthetic biology and biomanufacturing, providing strategic guidance for upgrading Shanxi's biopharmaceutical industry [2] - Local enterprises such as Shanxi Naan Biotechnology Co., Ltd. and Shanxi Jinbo Biopharmaceutical Co., Ltd. showcased their innovative achievements in biopharmaceuticals, highlighting the strong momentum of regional industrial development [2] - A roundtable discussion led by Professor Lu Lu from Fudan University focused on technological breakthroughs in the recombinant humanized collagen industry, discussing challenges and opportunities for future industrial development [2][3] Group 3 - Following the event, expert teams conducted on-site services at key enterprises, assessing their R&D laboratories and production bases to understand their needs in technology development and results transformation [3] - The Shanxi transformation demonstration area's officials emphasized that the event not only gathered high-end wisdom for the biopharmaceutical industry but also established a high-level platform for deep interaction between talent and industry [3] - Future plans include optimizing the talent development ecosystem and promoting the deep integration of the "four chains" to support the biopharmaceutical industry as a new driving force for Shanxi's emerging industrial development [3]